LAB/B: Exceptional 2024 results: strong sales, record profits, margin expansion, and robust cash flow

About this update from Genomma Lab Internacional Sab De Cv Class B

Q4 and full year 2024 saw double-digit sales and profit growth, with EBITDA and net income surging, margins expanding, and record free cash flow. Growth initiatives and reinvestment of productivity gains are set to accelerate future performance, with stable dividends and low leverage maintained. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genomma Lab Internacional Sab De Cv Class B